Radiotherapy and the Tumor Microenvironment: From Basic Mechanisms to Clinical Translation
A special issue of Cancers (ISSN 2072-6694).
Deadline for manuscript submissions: 31 October 2026 | Viewed by 48
Special Issue Editors
Interests: immunotherapy; tumor microenvironment; biomarkers; radiotherapy late effects; microbiome
Special Issues, Collections and Topics in MDPI journals
Interests: immunotherapy; cancer immunology; radiotherapy; pre-clinical models; tumour microenvironment; ageing microbiome
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Around half of cancer patients receive radiotherapy as part of their cancer treatment. Whilst the ability of radiotherapy to induce cell death through DNA damage is well known, the interplay between the immune system and radiotherapy is complex, and its role in patient outcomes is unclear. Animal models suggest that T-cells can be critical for the therapeutic effect of radiotherapy, but instances of abscopal responses are rarely described in the clinical setting. Furthermore, combination trials of radiotherapy and immune checkpoint inhibitors have often failed to deliver the benefits seen in pre-clinical models. Thus, to develop effective radiotherapy–immunotherapy combinations it is critical to understand the immune effects of radiotherapy, both locally in the tumor microenvironment and systemically. Identification of novel biomarkers are urgently needed to drive a more personalized approach to combining radiotherapy with immuno-oncology agents.
Dr. Eleanor J. Cheadle
Dr. Jamie Honeychurch
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- radiotherapy
- tumor microenvironment
- immune response
- biomarkers
- stroma
- immunogenic cell death
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
